1. Scrip
  2. >>Therapy Areas
  3. >>Alimentary/Metabolic

Quick Listen: Scrip's Five Must-Know Things

 
• By Ian Haydock

In this week's podcast edition of Five Must-Know Things: J&J interested in differentiated obesity assets; Kerendia hits in heart failure; strong HERCULES data keep Sanofi’s MS plans alive; WCLC preview; and Mankind sets eyes on 5x growth.

Scrip Five Must Know Things
weekly audio roundup of selected content from Scrip's global team

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip‘s global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 6 September 2024, including: Johnson & Johnson interested in differentiated obesity assets; Kerendia hits in heart failure; strong HERCULES data keep Sanofi’s MS plans alive; WCLC preview; and Mankind Pharma Ltd. sets eyes on 5x growth.

This and all our other podcasts are available on the Citeline channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "J&J Interested In ‘Differentiated’ Obesity Assets" - Scrip, 4 September, 2024.)

(Also see "ESC: Kerendia Hits In Heart Failure, But Usage Unclear" - Scrip, 1 September, 2024.)

(Also see "Strong HERCULES Data Keep Sanofi’s MS Plans Alive" - Scrip, 2 September, 2024.)

(Also see "WCLC Preview: ADCs, Bispecifics And Other Targeted Therapies Command Attention" - Scrip, 2 September, 2024.)

(Also see "Fast And Furious – Leqvio Licensed, Bharat Serums In Bag, Mankind Sets Eyes On 5X Growth" - Scrip, 3 September, 2024.)

Citeline · Scrip’s Five Must-Know Things - 9 September 2024

Open Media

More from Alimentary/Metabolic

Viking Rapidly Advancing Oral And Injectable VK2735 For Obesity

 
• By Joseph Haas

In its Q2 update, Viking reported that Phase III trials of subcutaneous VK2735 are under way, and that it expects Phase II data for an oral formulation before year’s end.

Obesity Beyond GLP-1s: Amylins – The Next Frontier

 
• By Aakash Babu

In this series of articles, we look at different mechanisms of actions beyond GLP-1s that could determine the obesity drug landscape in the coming years. First on our list – amylin receptor agonists, which analysts expect to grow into a $50bn market opportunity.

In Brief: Kezar Plots Lupus Revival For Zetomipzomib As FDA Lifts Hold On Hepatitis Trial

 
• By Manas Mishra

The go-ahead to resume a trial for its only drug candidate, zetomipzomib, in hepatitis could give Kezar a glimmer of hope of reviving another halted study in lupus nephritis.

Kailera Eyes Global Obesity Market With Hengrui’s Phase III Dual Agonist

 
• By Joseph Haas

With China’s Hengrui reporting successful Phase III data for its dual GLP-1/GIP agonist, licensee Kailera is readying plans to demonstrate better efficacy than current obesity drugs.

More from Therapy Areas

Memo Therapeutics Plans BK Virus Therapy Phase III Despite Trial Miss

 
• By Manas Mishra

Pointing to data that show a benefit in reducing viral load and the histological signs of the infection, Memo says its drug, potravitug, could become the first therapy to treat BK polyomavirus in kidney transplant recipients.

Viking Rapidly Advancing Oral And Injectable VK2735 For Obesity

 
• By Joseph Haas

In its Q2 update, Viking reported that Phase III trials of subcutaneous VK2735 are under way, and that it expects Phase II data for an oral formulation before year’s end.

Leo Looks To Grow In US After Hand Eczema Cream Approval

 
• By Kevin Grogan

The Danish medical dermatology specialist doubles boosts its sales force ahead of the launch of Anzupgo.